
Opinion|Videos|February 9, 2026
Barriers to Managing Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs help overcome social and systemic barriers to Alzheimer care.
Advertisement
Episodes in this series

Panelists discuss how social, financial, and systemic challenges hinder Alzheimer management. Limited access to specialists, diagnostic costs, and caregiver burnout are recurring themes.
Panelists discuss how APPs advocate for patients by navigating insurance processes, connecting families with resources, and promoting equitable access to care regardless of socioeconomic status.
Panelists discuss how addressing these barriers requires policy awareness and community outreach. APPs’ holistic approach positions them as champions of accessible, patient-centered care.
Advertisement
Related to this article

Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.
Advertisement
Advertisement
Trending on AJMC
1
Complicated UTI Care Strained by Unclear Goals, Access Gaps
2
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
3
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
4
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
5

